Latest News
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
27 May 2022 - - US-based clinical-stage biopharmaceutical company Xencor, Inc. (NASDAQ: XNCR) has reported initial dose-escalation data from the Phase 1 study evaluating XmAb104, a PD-1 x ICOS bispecific antibody, in patients with advanced solid tumo...
Tvardi Therapeutics' TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis
27 May 2022 - - US-based clinical-stage biopharmaceutical company Tvardi Therapeutics, Inc's lead product, TTI-101, has been granted Orphan Drug Designation by the US Food and Drug Administration for the treatment of idiopathic pulmonary fi...
Scioto Biosciences Posts Top-Line Results of SB-121 in a Phase Ib Trial in Patients Diagnosed with Autism Spectrum Disorder
27 May 2022 - - US-based clinical-stage biotechnology company Scioto Biosciences, Inc has released top-line results of its Phase Ib trial of lead asset, SB-121, based on its novel microbiome delivery platform, Activated Bacterial Therapeutics, w...
US FDA Accepts Reata Pharmaceuticals Filing, Grants Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich's Ataxia
27 May 2022 - - The US Food and Drug Administration has accepted for filing and granted Priority Review of US-based clinical-stage biopharmaceutical company Reata Pharmaceuticals, Inc's (NASDAQ: RETA) New Drug Application for omaveloxolone ...
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis
27 May 2022 - - The US Food and Drug Administration has granted Fast Track designation to US-based pharmaceutical company Pfizer Inc's (NYSE: PFE) investigational combination therapy for the treatment of non-alcoholic steatohepatitis with l...